Quark Pharmaceuticals Inc., Novartis Corporation (NVS) Sign $670-Mln Drug Deal
8/18/2010 7:20:26 AM
More...
|
Quark Pharmaceuticals Inc. (QURK)'s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
6/28/2010 9:15:42 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
6/24/2010 10:59:56 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
6/15/2010 10:11:53 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Closes $10 Million Financing
6/10/2010 6:49:15 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema
5/17/2010 11:16:40 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Development Partner Pfizer Inc. (PFE) Presents In Vivo Activity of PF-04523655 at ARVO
5/6/2010 11:46:55 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress
5/5/2010 9:04:16 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) To Present Phase I Data for QPI-1002 in Delayed Graft Function at American Transplant Congress
5/5/2010 8:57:10 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
3/1/2010 9:02:37 AM
More...
|
|